Location: Warren, New Jersey, United States
Job Category: Research and Early Development
Work Location: 7 Powder Horn Drive 07059
Organization: Computational Biology
Employee Status: Full-time
Job Type: Regular
Other Locations: United States-Washington-Seattle
At Celgene Corporation, we’re committed to changing the course of human health through bold pursuits in science, life-enhancing therapies and a promise to always put patients first. The Informatics and Predictive Sciences (IPS) department is made up of highly skilled and collaborative individuals who are fueled by the impact they make on the world through our work.
To help us achieve our mission, we are hiring a Senior Scientist, CAR-T Biological Data Science to join our team. This position can be based at our site in Warren, NJ or Seattle, WA.
What great looks like in this role
Our ideal Senior Scientist, CAR-T Biological Data Science candidate is a talented and detail oriented collaborative computational researcher. You have potential to be a leader in the industry by applying your excellent communication skills and highly collaborative approach to achieving the best results. You also have interest and hands-on expertise in the inter-disciplinary application of advanced analytical methods to life sciences and clinical datasets. You’ll use your skills to drive application of statistical and machine learning methods to identify critical patient and manufacturing factors in cellular therapies that affect efficacy, potential toxicities, and product consistency. This is a great opportunity for scientists looking to impact delivery of truly innovative and life-changing therapies for complex diseases of unmet medical need.
Objectives of this Role
- Play a key scientific role in leveraging innovative computational analysis strategies across a variety of biological and manufacturing data sources to empower data-driven decisions in the development of next generation cellular therapies.
- Work alongside Global Product Development Organization (GPDO) team members in New Jersey and Seattle, R&D team members in the Immuno-Oncology and Cellular Therapy Thematic Center of Excellence (IO/CT TCoE), and global IPS colleagues engaged in computational research into therapeutic mechanisms of action, efficacy in patient populations and reduction of potential toxicities.
- Application of machine learning and pattern recognition approaches to identify robust relationships between aspects of the cell therapy manufacturing process, properties of the resulting therapeutic product and clinical end points. The product properties in scope include molecular and cellular phenotypes, cellular functional assays, and clinical trial outputs. Algorithmic approaches involved will include supervised classification and regression, unsupervised learning and outlier detection, alongside data integration and biological interpretation methods.
Daily and Monthly Responsibilities
- Develop algorithmic and data-driven approaches aligned to cell therapy development objectives, including state-of-the-art methods from related fields.
- Develop novel integrative analysis strategies for molecular profiling data sets including RNA-seq, ATAC-seq, immune sequencing, high dimensional flow cytometry, and single cell sequencing to define critical therapeutic attributes.
- Engage directly with colleagues and as part of project teams focused on optimizing our manufacture of innovative cell therapies, lending analytics expertise to biological and technical subject matter experts as required.
- Collaborate with IPS, IO/CT and GPDO colleagues in areas of synergy and integrate data and methods applied in other business functions.
- Contribute to broader data analysis and predictive methods strategies across IPS as required, including assessment of third-party capabilities.
- Present strategies, approaches, results and conclusions to a publishable standard.
- Contribute to strategic collaborations with academic and commercial collaborators to benefit therapeutic programs.
- Catalyze a predictive culture across the GPDO function, by demonstrating benefits of leading analytical research in key application scenarios.
Knowledge and skills required
- Ph.D. in bioinformatics, computational biology, statistics, computer science, or related fields from a recognized higher-education establishment; alternatively, a Ph.D. in immunology or genetics with a very strong publication record demonstrating computational expertise and the ability to analyze high throughput datasets.
- 6+ years post-doctoral experience with predictive analytical research in solving biological problems in academic, clinical, or biotechnology environments. Strong publication record demonstrating use of analytical methods to elucidate and drive decisions in complex research scenarios, with focus on pattern recognition.
- Experience analyzing high dimensional cytometry or bulk and single cell sequencing data (e.g., flow cytometry, RNA-seq, ATAC-seq, immune sequencing).
- Fluency in Unix Bash, R, and Python and collaborative development skills using version control systems (e.g. Git).
- In-depth knowledge of contemporary techniques, paradigms, application scenarios, and frameworks in machine learning and data-mining (e.g. caret, scikit-learn, TensorFlow).
- Proven problem-solving skills, collaborative nature, and adaptability across disciplines.
- Ability to work independently and as a member of a multidisciplinary and global analytical research team in a fast-paced environment.
- Fluent verbal and written English language skills.
- Experience with notebook-based reproducible analysis tools (e.g. Jupyter, R Markdown) preferred.
- Background knowledge in aspects of molecular biology, cancer biology, and immunology and/or related bioinformatics and computational biology approaches preferred.
COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
"At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients."
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.